Quarterly revenues increased 6% over the same quarter last year to $2.1 billion, or 7% on a normalized and constant currency basis Closed 3,800 deals across more than 3,100 customers in Q1 Accelerated ...

STAMFORD, Conn.--(BUSINESS WIRE)--Altus Power, Inc. (NYSE: AMPS) ("Altus Power" or the "Company"), the largest commercial scale provider of clean, electric power, today announced its financial results ...

For the three and nine months ended September 30, 2025, net revenues were $39.9 million and $111.4 million as compared to $33.3 million and $87.7 million during the same periods in 2024, representing ...

The reconciliation includes two scenarios that illustrate our projected free cash flow range for 2025. The amounts used in the reconciliation are subject to many variables, some of which are not under ...

About the Use of Non-GAAP Financial Measures:To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA and adjusted EPS as non-GAAP financial measures to ...

Adjusted EBITDA is defined as earnings before net interest expense, income taxes, depreciation, amortization and accretion expense, non-cash unit-based compensation expense, gains and losses on ...

CUPERTINO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on low and negative carbon intensity products that lower ...

We've identified the following companies as similar to Accretion Pharmaceuticals Ltd because they operate in a related industry or sector. We also considered size, growth, and various financial ...

STAMFORD, Conn.--(BUSINESS WIRE)-- Altus Power, Inc. (NYSE: AMPS) (“Altus Power”, the “Company” or “us”), a leading commercial scale provider of clean, electric power, today announced its financial ...